ImmunityBio Inc IBRX 深 沪
交易中 05-11 12:11:24 美东时间
8.26
-0.250
-2.94%
华盛通- 最 高8.69
- 今 开8.43
- 成交量 589.22万股
- 最 低 7.36
- 昨 收 8.5099
- 总市值 328.75万
- 52周最高 12.43
- 市盈率 静 --
- 换手率 1480.46%
- 52周最低 1.95
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 45.42
- 量 比 1.28
- 振 幅 15.63%
- 历史最低 0.93
- 每 手 1
- 风险率 2.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Flags Anktiva Claims While ImmunityBio Pushes Regulatory Fixes
ImmunityBio responds to FDA warning on Anktiva promotions, while NCCN update and rising sales support growth narrative.
04-06 23:14
ImmunityBio Submits FDA Response On Ad, Podcast Issues; Co. Tells FDA TV Ad Never Aired, Responds On Podcast
Company initiated a comprehensive review of promotional materials and is implementing enhanced advertising compliance measures, including expanded promotional review protocols, executive training, and external regulatory
04-06 19:37
Why Are ImmunityBio Shares Rising Today?
Shares of ImmunityBio, Inc. (NASDAQ: IBRX) are lifting after the company announced it secured $75 million in non-dilutive financing.
04-01 00:48
FDA Issues Warning To ImmunityBio Over Misleading Anktiva Promotions, Says False & Misleading Claims/Misbranded
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/immunitybio-inc-725468-03132026
03-24 21:37
Lucid Tops The Most-Shorted Stock List—Here Are 9 More Short Targets
Lucid, CleanSpark and Hims & Hers are the top 3 most shorted stocks. Here's the rest of the top ten.
03-12 03:20
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
ImmunityBio resubmits the ANKTIVA application to the FDA after a prior setback.
03-09 23:03
ImmunityBio Investors Rally Behind Cancer Trial Milestone
ImmunityBio stock rises after 85% response rate in bladder cancer study, topping BCG alone; FDA filing planned for 2026.
02-26 21:57
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio stock climbs after Anktiva sales surge 750%, revenue beats estimates, and new Saudi partnership fuels growth.
02-26 02:02
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate
With 40% short interest and rising hedge fund buying, ImmunityBio's explosive rally may be entering its most volatile phase yet.
02-25 22:09
Earnings Breakdown: ImmunityBio Q4
ImmunityBio (NASDAQ:IBRX) released its Q4 earnings on Monday, February 23, 2026...
02-23 20:14
